News

Stay up to date with the latest activity at Richmond Pharmacology

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

20
October 2020

Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)

View article

Richmond Pharmacology supports ReViral with the development of Sisunatovir

9
September 2020

ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.

View article

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

17
August 2020

Richmond Pharmacology early phase drug development update.

View article

Dr Jorg Taubel, CEO of Richmond Pharmacology, features on the PM Live website, discussing clincial trials and COVID-19

11
August 2020

Dr Jorg Taubel discusses some of the steps taken at Richmond Pharmacology to ensure clinical trials can continue to operate at a high standard throughout the COVID-19 pandemic.

View article

COVID-19 – External Monitoring Guidelines

1
July 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

View article

Statement: COVID-19

23
March 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.

View article
More about usAdaptive Phase I, II & IIIBridging StudiesTQT StudiesPatient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more
© 2020 Richmond Pharmacology
EventsDisclaimerWebsitesSitemapPrivacy
Website by WOD.agency